Green D, Ts'ao C H
Department of Medicine, Northwestern Memorial Hospital, Chicago, IL.
J Lab Clin Med. 1990 Feb;115(2):144-7.
Extensive studies performed over the past 6 years have shown that a degradation product of hematin produces a unique coagulopathy, characterized by thrombocytopenia with platelet degranulation, alteration in the function of numerous clotting and fibrinolytic proteins, and reversible changes in endothelial cells. With the use of degraded hematin, it can be demonstrated that platelet aggregation is stimulated, that platelet adhesion to endothelial cells is enhanced, that the dissociation of factor VIII: C from von Willebrand factor is inhibited, and that the binding of the factor VII/von Willebrand factor complex to platelets is impaired. Even freshly reconstituted solutions of sorbitol-stabilized hematin affect hemostasis and induce thrombophlebitis, presumably because of in vivo degradation of the hematin. Recently, a new formulation of hematin, heme arginate, has been shown to be extraordinarily stable and to have virtually no effects on coagulation. This review compares and summarizes the effects of these various hematin compounds on hemostasis.
过去6年进行的大量研究表明,血红素的一种降解产物会产生一种独特的凝血病,其特征为血小板减少伴血小板脱颗粒、多种凝血和纤溶蛋白功能改变以及内皮细胞的可逆性变化。使用降解的血红素可以证明,血小板聚集受到刺激,血小板与内皮细胞的黏附增强,因子VIII:C与血管性血友病因子的解离受到抑制,并且因子VII/血管性血友病因子复合物与血小板的结合受损。即使是新配制的山梨醇稳定血红素溶液也会影响止血并诱发血栓性静脉炎,可能是因为血红素在体内发生了降解。最近,一种新的血红素制剂——精氨酸血红素,已被证明具有极高的稳定性,并且对凝血几乎没有影响。本综述比较并总结了这些不同血红素化合物对止血的影响。